Quick Summary
- SR9009 (Stenabolic) is a synthetic REV-ERB agonist — not a SARM despite being lumped with them in marketing — that modulates the circadian-clock-controlled metabolic gene network.
- Mechanism: binds and activates the REV-ERBα/β nuclear receptors, which suppress BMAL1 and drive shifts in mitochondrial biogenesis, fatty-acid oxidation, and glucose handling.
- Built for: athletes and biohackers seeking metabolic efficiency, fat oxidation, and exercise-mimicking effects without androgen-receptor activity or HPG suppression.
- Differentiator: poor oral bioavailability and short half-life make traditional dosing difficult; the compound is more research-grade than practical for most users — which the marketing rarely admits.
- Tony Huge angle: high mechanistic interest, modest practical impact. Worth understanding the circadian-metabolism angle even if SR9009 isn’t the final tool you use.
Deep Biochemistry of SR9009
SR9009 was developed in 2012 in the Burris lab at Scripps Florida as a chemical probe to study REV-ERB function — not as a therapeutic. It is a small-molecule agonist of REV-ERBα and REV-ERBβ, two nuclear receptors that function as transcriptional repressors of the circadian-clock-controlled gene network.
The circadian clock is built on a transcriptional feedback loop: BMAL1 and CLOCK heterodimerize and drive expression of clock-output genes including PER, CRY, and the REV-ERBs. The REV-ERBs then feed back and repress BMAL1, completing the loop. Activating REV-ERB pharmacologically pushes the loop in one direction — BMAL1 is suppressed, and a downstream network of metabolic genes shifts accordingly.
Specifically, REV-ERB activation suppresses gluconeogenesis, increases mitochondrial biogenesis, increases skeletal muscle fatty-acid oxidation, decreases adipogenesis, and reduces inflammation. In mice, SR9009 produced effects superficially similar to exercise — increased running endurance, improved glucose tolerance, decreased fat mass — leading to the press-friendly label “exercise in a pill.”
The pharmacokinetics tell a different story. SR9009 has poor oral bioavailability (estimated 2-3% in some studies), a half-life of approximately 1-2 hours, and significant first-pass metabolism. The murine studies that produced the dramatic effects used intraperitoneal injection at 100 mg/kg — a route and dose that don’t translate cleanly to oral human protocols. Most “SR9009 results” reported by users are likely confounded by training, diet, or other compounds in their stack.
Tony huge laws of Biochemistry Physics — Law 2 Applied
SR9009 illustrates the tony huge laws of Biochemistry Physics, Law 2: Chain Optimization, in a cautionary way. REV-ERB sits inside a long transcriptional chain — receptor binding → transcription factor modulation → downstream gene expression → protein synthesis → metabolic effect. Each link has its own kinetics. If the upstream link (REV-ERB occupancy) is intermittent and brief because of poor pharmacokinetics, the downstream effects never accumulate to a functional level. The chain has the right components, but the slowest link — sustained REV-ERB occupancy — is the bottleneck. This is what makes SR9009 a better research tool than a practical compound, and the lesson generalizes: mechanism on paper doesn’t guarantee mechanism in vivo if you can’t get the molecule to the target at the right concentration for long enough.
Natural Plus Protocol — SR9009
If you’re going to run SR9009 despite the pharmacokinetic limitations, the most evidence-grounded approach is: 20-40 mg per day, split into 4-5 doses across the day to compensate for the short half-life, with doses timed in the morning and through the active phase (REV-ERB activation during the rest phase may actually disrupt rather than enhance circadian rhythm). Take with a meal containing some dietary fat to improve absorption modestly. Cycle length: 4-8 weeks; longer cycles do not appear to produce additional benefit given the pharmacokinetic ceiling.
Side-effect profile at typical doses is mild — no androgen-receptor activity, no HPG axis suppression, no obvious hepatotoxicity at moderate doses. PCT is not relevant. The injectable form circulates in research-chemical markets and would theoretically achieve better pharmacokinetics, but quality and safety are uncontrolled. Monitor: liver enzymes (out of conservatism), lipid panel, sleep architecture (REV-ERB activation can blunt sleep depth if timing is wrong).
Stacking Recommendations
| Stack Compound | Pathway | Why It Synergizes |
|---|---|---|
| Cardarine (GW-501516) | PPARδ agonist / fatty acid oxidation | Both drive fat-oxidation gene programs through related but distinct nuclear receptors. The classic ‘metabolic stack,’ though Cardarine has its own concerns. |
| Berberine | AMPK activation / glucose handling | Berberine activates AMPK which feeds into the metabolic shift SR9009 induces. Cheap, oral, well-characterized — fills the practical gap SR9009’s pharmacokinetics leave. |
| MOTS-c | Mitochondrial-nuclear signaling | MOTS-c activates AMPK and shifts metabolic state from a different upstream entry point. Combined coverage of the metabolic-flexibility network. |
| Cold exposure / fasted morning cardio | Behavioral metabolic stress | Behavioral mechanisms of mitochondrial biogenesis and fat oxidation are far more reliable than SR9009 pharmacology. the honest take: build the behavioral foundation first. |
Target Audience
Athletes interested in the circadian-metabolism mechanism who understand the pharmacokinetic caveats. Researchers and biohackers running personal n-of-1 experiments who want to characterize their own response. People in body-composition phases who already have the foundational training and diet locked in and want to test whether adding a pharmacological metabolic-shift compound moves their personal needle. Not for: anyone expecting “exercise in a pill” results — those came from murine intraperitoneal dosing that doesn’t translate. Not for anyone with circadian-rhythm disorders or shift workers without close attention to dosing timing.
Expected Timeline
| Timeframe | What to Expect |
|---|---|
| Week 1-2 | Subtle metabolic shifts. Some users report easier fasted training; subjective fatigue resistance during long sessions. |
| Week 4 | Modest body-composition shifts on a controlled diet — likely additive to whatever the training and nutrition would have produced alone. |
| Week 6-8 | Plateau established. The pharmacokinetic ceiling limits how much further benefit accumulates. |
| Post-cycle | Effects fade within days of discontinuation. SR9009 is not a compound that ‘rewires’ anything — it produces transient gene-expression shifts as long as the drug is present. |
Interesting Perspectives on SR9009
The contrarian take that needs to be more widely understood: SR9009 has been over-marketed by the SARMs industry as a practical compound when the pharmacokinetic data clearly shows it isn’t. The animal studies that generated the hype used routes and doses that human oral protocols cannot replicate. The compound was designed as a research chemical to study REV-ERB function — Burris and colleagues never claimed it was therapeutically practical. Newer REV-ERB agonists with better pharmacokinetic profiles (SR12418, GSK4112 derivatives) are in development and would be more meaningful if and when they reach research-chemical or clinical availability.
That said, the mechanism itself is real and the cross-domain implications are significant. REV-ERB modulation has been studied for metabolic syndrome, cardiovascular disease, sleep disorders, neuroinflammation, and even cancer biology. The drug-discovery effort is active. SR9009 is to circadian metabolism what early proof-of-concept compounds usually are: imperfect first-generation tools that establish a target is worth pursuing.
Cross-domain connection: the circadian-clock metabolism research underpinning SR9009 has produced one of the most reliable interventions in metabolism: time-restricted eating (TRE). The mechanism by which TRE improves metabolic health overlaps significantly with what SR9009 attempts pharmacologically. The behavioral intervention is far more reliable, much cheaper, and doesn’t depend on pharmacokinetic luck. the strongest argument against SR9009 may be that disciplined TRE delivers most of the benefit at zero risk.
References
- Solt LA et al. “Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists.” Nature, 2012.
- Woldt E et al. “Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy.” Nat Med, 2013.
- Banerjee S et al. “Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviour.” Nat Commun, 2014.
- Dierickx P et al. “SR9009 has REV-ERB-independent effects on cell proliferation and metabolism.” PNAS, 2019.
- Bugge A et al. “Rev-erbα and Rev-erbβ coordinately protect the circadian clock and normal metabolic function.” Genes Dev, 2012.
Frequently Asked Questions
What is SR9009?
SR9009 (Stenabolic) is a synthetic REV-ERB agonist developed in 2012 as a research chemical to study the REV-ERB nuclear receptors. It modulates circadian-clock-controlled metabolic gene expression.
Is SR9009 a SARM?
No. SR9009 is often marketed as a SARM but does not bind the androgen receptor and has nothing to do with the SARM mechanism. It is a nuclear receptor agonist for a different receptor family entirely.
Does SR9009 actually work — is it ‘exercise in a pill’?
The ‘exercise in a pill’ headlines came from murine intraperitoneal dosing. In humans taking oral SR9009, the pharmacokinetics (poor bioavailability, short half-life) limit the practical effect substantially. Real but modest.
How is SR9009 dosed?
20-40 mg per day split into 4-5 doses to compensate for the short half-life. Take during the active phase (morning to mid-afternoon), not evening. Cycle 4-8 weeks.
Should I take SR9009 or just do time-restricted eating?
Honest answer: time-restricted eating delivers most of the circadian-metabolism benefit reliably and free. SR9009 is interesting mechanistically but the behavioral intervention is the high-confidence move. Stack TRE with SR9009 if you want both.
Internal Links
For a comparison compound also marketed in the SARMs adjacent space, read about Cardarine. For the broader SARMs/PEDs context, see the supplements chapter. For mitochondrial-axis compounds, see MOTS-c and SS-31.
The Enhanced Path Forward
This article is one piece of the larger Enhanced Athlete Protocol — a complete framework for hormones, training, nutrition, supplements, recovery, peptides, and bloodwork. Read the hub. build your stack with intention. the foreverman is engineered, not stumbled into.